健康元(600380.SH):子公司麗珠集團與LTS簽署藥品授權合作協議
格隆匯 7 月 3日丨健康元(600380.SH)公佈,健康元藥業集團股份有限公司(以下簡稱:本公司)控股子公司麗珠醫藥集團股份有限公司(以下簡稱:麗珠集團)於2020年7月3日與LTSLohmannTherapie-SystemeAG(以下簡稱:LTS)簽署了《授權合作協議》(以下簡稱:協議或本協議),LTS將授予麗珠集團阿塞那平透皮貼劑(以下簡稱:授權產品)若干知識產權下的獨家、包含特許權使用費、可轉授權的許可權。根據本協議約定,麗珠集團將與LTS合作開發授權產品,授權產品上市後麗珠集團將擁有其在中國大陸、香港特別行政區及澳門特別行政區,不含台灣地區(以下簡稱:授權區域)的獨家商業化權利。麗珠集團需支付授權產品在研發、申報及上市後各階段相應的費用、里程碑金及銷售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.